Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAP3K7
REST API REST API
Homo sapiens
MAP3K7 is differentially expressed in 313 experiments: 140 organism parts: liver, bone marrow, ... (138 more);, 248 disease states: normal, prostate carcinoma, ... (246 more);, 107 cell types 458 cell lines 43 compound treatments and 85 other conditions.
Synonyms TAK1, MEKK7
Orthologs Map3k7 (Mus musculus)   E1C063_CHICK (Gallus gallus)   map3k7 (Danio rerio)   Map3k7 (Rattus norvegicus)   M3K7_BOVIN (Bos taurus)   F6PZN7_CIOIN (Ciona intestinalis)   Takl2 (Drosophila melanogaster)   Tak1 (Drosophila melanogaster)   map3k7 (Xenopus laevis)   MAP3K7 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, Toll signaling pathway, cytosol, protein binding, MAP kinase kinase kinase activity, innate immune response, negative regulation of apoptosis, MAPKKK cascade, protein tyrosine kinase activity, transforming growth factor beta receptor signaling pathway, MAP kinase kinase activity, stress-activated MAPK cascade, endosome membrane, positive regulation of JUN kinase activity, positive regulation of JNK cascade, activation of MAPK activity, I-kappaB kinase/NF-kappaB cascade, activation of MAPKK activity, ATP binding, magnesium ion binding, transferase activity, transferring phosphorus-containing groups, nucleotide binding, kinase activity, histone H3 acetylation, protein serine/threonine kinase activity, JNK cascade, positive regulation of NF-kappaB transcription factor activity, signal transduction, protein kinase activity, positive regulation of I-kappaB kinase/NF-kappaB cascade, toll-like receptor 4 signaling pathway, T cell receptor signaling pathway, positive regulation of T cell activation, neural tube formation, toll-like receptor signaling pathway, activation of innate immune response, positive regulation of interleukin-2 production, positive regulation of T cell cytokine production, toll-like receptor 3 signaling pathway, activation of NF-kappaB-inducing kinase activity, toll-like receptor 2 signaling pathway, MyD88-dependent toll-like receptor signaling pathway, IkappaB kinase complex, I-kappaB phosphorylation, protein phosphorylation, MyD88-independent toll-like receptor signaling pathway, Ada2/Gcn5/Ada3 transcription activator complex, toll-like receptor 1 signaling pathway, nucleotide-binding oligomerization domain containing signaling pathway
InterPro Term Prot_kinase_cat_dom, MAPKKK7, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q9NZ70, Q9UG54, O43318, E7EMD4
Search EB-eye ENSG00000135341
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (43 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-18005
452 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-26672, E-GEOD-13987
fibroblast
1
2
E-GEOD-26672, E-GEOD-3204, E-GEOD-3920
mononuclear cell
1
E-GEOD-6053
purified CLL B cells from peripheral blood
1
E-GEOD-22529
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-2280, E-GEOD-16363, ... (70 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
myxoid liposarcoma
2
E-GEOD-6481, E-MTAB-62
extranodal NK/T-cell lymphoma
2
E-TABM-702, E-GEOD-19067
Classic-KS, HIV-, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
242 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
none
4
5
E-GEOD-5824, E-MEXP-1230, E-TABM-868, E-MEXP-1958, E-GEOD-412, ... (9 experiments)
selenium
1
E-MEXP-1327
ethanol
1
E-GEOD-3113
ponasterone A
1
E-GEOD-3113
N-nitrosodimethylamine
1
E-GEOD-6907
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1140, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-MEXP-2280, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-3720, E-TABM-26, ... (37 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-22541, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.448 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM